Nanosonics Ltd

NAN: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|>#%N^NLOCK|s^<<<LOCK|!&?KL<

Nanosonics Earnings: Shares Undervalued With Strong Recovery

As we expected, narrow-moat Nanosonics’ fiscal 2024 sales of AUD 170 million were flat in constant currency. While hospital budget constraints weighed on sales, particularly in the first half, conditions and ultrasound volumes improved. Second-half sales were up a strong 14% sequentially on the first half to AUD 90 million. The full-year EBIT of AUD 9 million was stronger than we expected, mainly on an upper end of guidance gross margin of 78%.

Sponsor Center